| 產(chǎn)品編號(hào) | bs-5107R |
| 英文名稱 | PON1 Rabbit pAb |
| 中文名稱 | 芳香酯酶1(對(duì)氧磷酶)抗體 |
| 別 名 | A esterase 1; A-esterase 1; Aromatic esterase 1; Arylesterase B type; ESA; Esterase A; K 45; K-45; MVCD5; Paraoxonase 1; Paraoxonase; Paraoxonase B type; Paraoxonase1; PON 1; PON; PON-1; PON1_HUMAN; Serum aryldiakylphosphatase; Serum aryldialkylphosphatase 1; Serum paraoxonase/arylesterase 1. |
| 研究領(lǐng)域 | 腫瘤 心血管 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 脂蛋白 新陳代謝 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Mouse (predicted: Human,Rat,Rabbit,Pig,Cow,Horse) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 40 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞外基質(zhì) 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PON1: 201-300/355 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
PON1 is synthesized primarily in the liver, and a portion is secreted into the plasma, where it is associated with high density lipoproteins (HDL). PON1 hydrolyzes the active metabolites of several other organophosphorus insecticides, as well as nerve agents such as sarin, soman and VX (lethal nerve agent). The PON1 polymorphism may be responsible for neurodegeneration and is considered to be an independent risk factor for Parkinson’s disease. Function: Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation. Subunit: Homodimer. Heterooligomer with phosphate-binding protein (HPBP). Interacts with CLU. Subcellular Location: Secreted, extracellular space. Tissue Specificity: Plasma, associated with HDL (at protein level). Expressed in liver, but not in heart, brain, placenta, lung, skeletal muscle, kidney or pancreas. Post-translational modifications: Glycosylated. The signal sequence is not cleaved. Present in two forms, form B contains a disulfide bond, form A does not. DISEASE: Microvascular complications of diabetes 5 (MVCD5) [MIM:612633]: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Homozygosity for the Leu-55 allele is strongly associated with the development of retinal disease in diabetic patients. Similarity: Belongs to the paraoxonase family. SWISS: P27169 Gene ID: 5444 Database links: Entrez Gene: 5444 Human Entrez Gene: 18979 Mouse Omim: 168820 Human SwissProt: P27169 Human SwissProt: P52430 Mouse Unigene: 370995 Human Unigene: 237657 Mouse Unigene: 20732 Rat |
| 產(chǎn)品圖片 |
Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PON1) Polyclonal Antibody, Unconjugated (bs-5107R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.
|
